Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Rev. colomb. reumatol ; 29(4)oct.-dic. 2022.
Article in English | LILACS | ID: biblio-1536200

ABSTRACT

Lipodystrophy is a pathological condition associated with an abnormal body adipose tissue redistribution. Facial lipoatrophy can be a consequence of congenital, acquired, or involutional. The lipograft is an autologous fat transplant, which constitutes a treatment option that provides volume, tissue regeneration, and advantages in relation to other fillers in autoimmune diseases. The aim is to highlight the filling action and the metabolic effect of facial lipotransfer, due to the grafted adipocytes survival, and the adipose tissue derived stem cells regenerative activity obtained by nano-fat in patients with facial lipoatrophy. Lipoinjection improves the architecture of the new dermis and increases its functional capacity. It is a treatment with autologous tissue (fatty graft) with great efficacy in relation to other alloplastic filler materials capable of exacerbating an inflammatory response mediated by antibody production.


La lipodistrofia es una condición patológica asociada a una redistribución anómala del tejido adiposo en el cuerpo. La lipoatrofia facial puede ser consecuencia de defectos congénitos, adquiridos o involutivos. El lipoinjerto es el trasplante de grasa autógena y constituye una opción de tratamiento que aporta volumen, regeneración tisular y ventajas en relación con otros materiales de relleno en enfermedades autoinmunes. Se busca resaltar la acción de relleno y el efecto metabólico de la lipotransferencia facial, por la supervivencia de los adipocitos injertados y la actividad regenerativa de las células madre provenientes del tejido adiposo obtenidas por nanofat en pacientes con lipoatrofia facial. La lipoinyección mejora la arquitectura de la nueva dermis y aumenta su capacidad funcional, es un tratamiento con tejido autógeno (injerto graso) con gran eficacia en relación con otros materiales de relleno aloplásticos capaces de exacerbar una respuesta inflamatoria mediada por la producción de anticuerpos.


Subject(s)
Humans , Female , Adult , Scleroderma, Localized , Therapeutics , Lupus Erythematosus, Cutaneous , Skin Transplantation , Skin and Connective Tissue Diseases , Connective Tissue Diseases , Cell- and Tissue-Based Therapy , Lipodystrophy
2.
Braz. dent. sci ; 22(4): 506-512, 2019. tab
Article in English | BBO, LILACS | ID: biblio-1024474

ABSTRACT

Introduction: Systemic lupus erythematosus is an autoimmune disease that affects multiple organs. It is well known that lupus patients have higher risk of osteoporosis, but if the disease affects mandibular cortical bone and alveolar bone is not fully established. Objective: The objective of this study was to evaluate periodontal disease defects and mandibular osteoporotic alterations in patients with lupus as compared to healthy patients using panoramic radiographs. Material and Methods: The panoramic radiographs of 72 patients with lupus and 360 healthy patients were evaluated for the presence of bone loss secondary to periodontal disease, classified as horizontal and vertical bone loss. We also assessed mandibular osteoporotic alterations by using the mandibular cortical index. Logistic regression analysis was applied to estimate the risk of mandibular osteoporotic alterations as well as horizontal and vertical bone loss in patients with lupus as compared to healthy patients. Results: There were no statistically significant differences between groups in the presence of horizontal bone defects and mandibular cortical indexes. However, patients with lupus demonstrated that patients with lupus were 2.17 more likely to present vertical bone loss than healthy patients. Conclusions: Patients with lupus might have higher risk of vertical bone loss than healthy patients due to pathophysiology of their disease. Further larger prospective studies should be performed to confirm our findings (AU)


Introdução: Os lúpus eritematoso sistêmico é uma doença autoimune que afeta múltiplos órgãos. Pacientes com lúpus têm maior risco de osteoporose, mas é necessário elucidar-se como a doença afeta o esqueleto maxilo-mandibular. Objetivo: O objetivo deste estudo foi avaliar defeitos ósseos por doença periodontal e alterações osteoporóticas mandibulares em pacientes com lúpus, em comparação com pacientes saudáveis, utilizando-se radiografias panorâmicas. Material e Métodos: As radiografias panorâmicas de 72 pacientes com lúpus e 360 pacientes saudáveis foram avaliadas quanto à presença de defeitos ósseos verticais e horizontais por doença periodontal. Foram também avaliadas as alterações osteoporóticas da mandíbula por meio do índice da cortical mandibular. A regressão logística foi aplicada para estimar o risco de alterações osteoporóticas mandibulares, bem como a perda óssea horizontal e vertical em pacientes com lúpus, em comparação com pacientes saudáveis. Resultados: Não houveram diferenças estatisticamente significantes entre os grupos no tocante à presença de defeitos ósseos horizontais quanto à redução da densidade mineral óssea aferida por meio do índice da cortical mandibular. No entanto, pacientes com lúpus apresentaram 2,17 mais risco à perda óssea vertical do que pacientes saudáveis. Conclusões: Pacientes com lúpus podem ter maior risco de apresentar defeito ósseo vertical do que pacientes saudáveis devido à fisiopatologia de sua doença. Novos estudos prospectivos devem ser realizados para confirmar estes achados (AU)


Subject(s)
Humans , Osteoporosis , Periodontal Diseases , Lupus Erythematosus, Cutaneous , Radiography, Panoramic , Bone Density , Lupus Erythematosus, Systemic
3.
Biociencias ; 13(1): [123-136], 2018. fig
Article in Spanish | LILACS, COLNAL | ID: biblio-969993

ABSTRACT

El lupus eritematoso sistémico (LES) esuna enfermedad de tipo autoinmune en donde existen múltiples factores que inducen una respuesta inmunológica no controlada en un individuo que genéticamente está predispuesto, presentándose una variedad de manifestaciones clínicas que muchas veces se convierten en un verdadero reto diagnóstico y terapéutico como es el caso de sus presentaciones en piel. Describiremos a continuación un caso de un paciente género masculino con diagnostico LES con lesiones cutáneas extensas severas con diagnóstico clínico yhistopatológico sugestivo de lupus ampolloso refractarias a tratamiento estándar con corticoterapia e inmunomoduladores con evolución tórpida en su curso, que requiere posteriormente inicio de terapia biológica con Belimumab observándose una remisión clínica significativa de las lesiones y contribuyendo además a disminuir las dosis de corticoides utilizadas desde su ingreso . Se revisaránaspectos en relación del LES en hombres en lo que refiere a epidemiologia, manifestaciones cutáneas, hallazgos histopatológicos, diagnóstico diferencial y opciones terapéuticas actuales.


Systemic lupus erythematosus (SLE) is an autoimmune disease in which multiple factors induce an uncontrolled immune response in an individual who is genetically predisposed, presenting a variety of clinical manifestations that often become a real diagnostic challenge and Therapeutic as in the case of their skin presentations. We will now describe a case of a malepatient with a SLE diagnosis with severe extensive skin lesions with clinical and histopathological diagnosis suggestive of blistering lupus refractory to standard treatment with corticosteroid therapy and immunomodulators with a morphologic evolution in their course, which then requires the initiation of biological therapy with Belimumab observed a significant clinical remission of the lesions and also contributing to decrease the doses of corticosteroids used since their entry. We will review aspects related to SLE in men in terms of epidemiology, cutaneous manifestations, histopathological findings, differential diagnosis and current therapeutic options


Subject(s)
Humans , Lupus Erythematosus, Cutaneous , Lupus Coagulation Inhibitor , Dermatology
4.
Rev. colomb. reumatol ; 23(3): 195-199, jul.-set. 2016. ilus, tab
Article in Spanish | LILACS | ID: biblio-960210

ABSTRACT

El síndrome de Gardner-Diamond o púrpura psicógena es una vasculopatía de presunto origen autoinmune que se caracteriza por una reacción cutánea localizada, asociada a situaciones de estrés emocional. Se presenta el caso de una paciente con lesiones equimóticas, dolorosas y de aparición intermitente, relacionadas con diversos eventos estresores, que habían sido manejadas como manifestación de lupus


Gardner-Diamond syndrome or psychogenic purpura is an vasculopathy characterized by a localized cutaneous reaction, associated with episodes of emotional stress or mental illness as trigger factors. A case of a female patient with multiple, intermittent, nodular, ecchymotic and painful lesions related to various stressing events that was treated as lupus is reported below


Subject(s)
Humans , Lupus Erythematosus, Cutaneous , Diagnosis, Differential
5.
Rev. chil. reumatol ; 29(3): 148-154, 2013. ilus, tab
Article in Spanish | LILACS | ID: lil-708067

ABSTRACT

Presents a case of a young woman with a recent diagnose of systemic lupus erythematosus (SLE), with a sligth initial skin condition that envolves into toxic epidermal necrolysis (TENS): On account of this case, areview is presented of the physiopathology, clinical presentation and treatment of this infrequent form of dermatological manifestation of (SLE).


Se presenta el caso de una joven con diagnóstico reciente de lupus eritematoso sistémico (LES), con compromiso cutáneo inicial leve que evoluciona hacia necrolisis epidérmico tóxica (NET). A propósito de ello, se revisa la fisioptología, presentación clínica y tratamiento de esta infrecuente forma de manifestación dermatológica de LES.


Subject(s)
Humans , Female , Adolescent , Lupus Erythematosus, Systemic/complications , Stevens-Johnson Syndrome/diagnosis , Stevens-Johnson Syndrome/etiology , Stevens-Johnson Syndrome/drug therapy , Immunologic Factors/therapeutic use , Immunoglobulins/therapeutic use , Stevens-Johnson Syndrome/physiopathology , Treatment Outcome
6.
Iatreia ; 25(3): 229-239, jul.-sep. 2012. ilus, tab
Article in Spanish | LILACS, COLNAL | ID: lil-649968

ABSTRACT

El lupus eritematoso sistémico ampolloso (LESA) es una manifestación infrecuente del lupus eritematoso sistémico (LES) causada por autoanticuerpos contra el colágeno tipo VII y otros componentes esenciales de la unión dermoepidérmica. Se presenta en pacientes que cumplen los criterios revisados de clasificación para LES del Colegio Americano de Reumatología y en presencia de alta actividad sistémica. El diagnóstico diferencial incluye otras enfermedades ampollosas autoinmunes como el penfigoide ampolloso, la epidermólisis ampollosa adquirida, la dermatosis ampollosa IgA lineal y la dermatitis herpetiforme las cuales también han sido informadas en LES.


Bullous systemic lupus erythematosus (BSLE) is an unusual cutaneous manifestation in systemic lupus erythematosus (SLE) caused by autoantibodies targeting type VII collagen and other essential constituents of the dermal-epidermal junction. This rare entity is observed in patients who meet the American College of Rheumatology revised criteria for SLE and usually in the context of increased systemic disease activity. Differential diagnoses of BSLE include other autoimmune bullous diseases such as bullous pemphigoid, epidermolysis bullosa acquisita, linear IgA bullous dermatosis and dermatitis herpetiformis which have also been reported in association with SLE.


Subject(s)
Female , Adult , Lupus Erythematosus, Systemic , Skin Diseases , Skin Diseases, Vesiculobullous , Autoimmune Diseases
7.
Rev. colomb. reumatol ; 16(4): 352-360, Dec. 2009. ilus, tab
Article in Spanish | LILACS | ID: lil-636811

ABSTRACT

El lupus ampolloso es una manifestación poco frecuente del lupus eritematoso sistémico (LES). Otras enfermedades ampollosas tales como el penfigoide ampolloso, epidermólisis ampollosa adquirida, dermatosis ampollosa Ig A lineal y dermatitis herpetiforme también han sido informadas en LES. Describimos un paciente que desarrolló lesiones ampollosas 14 días luego de iniciar terapia con altas dosis de glucocorticoides y ciclofosfamida para manifestaciones severas del LES (nefritis y hemorragia alveolar). Se confirmó el diagnóstico de lupus ampolloso. La respuesta al tratamiento con dapsona fue notable a las 48 horas. En este artículo revisamos la epidemiología, hallazgos clínicos, histopatológicos e inmunopatológicos; el diagnóstico diferencial y el tratamiento del LES ampolloso.


Bullous systemic lupus erythematosus (BSLE) is an unusual finding in systemic lupus erythematosus (SLE). Other bullous disorders such as bullous pemphigoid, epirdermolysis bullosa acquisita, linear IgA bullous dermatosis and dermatitis herpetiformis has also been reported in association with SLE. We described a patient who developed severe bullous lesions 14 days after high-dose systemic glucocorticoids and cyclophosphide therapies were initiated for severe SLE manifestations (nephritis and alveolar hemorrhage). A diagnosis of bullous SLE was made. Therapy with dapsone resulted in a marked clinical improvement of the bullous eruption within 48 hours. This article also discusses the epidemiology, clinical, histopathologic and immunopathologic features, differential diagnosis and the treatment of BSLE.


Subject(s)
Humans , Male , Adult , Therapeutics , Dapsone , Lupus Erythematosus, Systemic , Epidemiology , Cyclophosphamide , Diagnosis , Glucocorticoids
8.
Rev. bras. reumatol ; 48(5): 283-290, set.-out. 2008. ilus, tab
Article in Portuguese | LILACS | ID: lil-500201

ABSTRACT

O lúpus cutâneo é a principal manifestação clínica do lúpus eritematoso sistêmico. Diferentes formas de apresentações clínicas e histopatológicas compõem o quadro cutâneo. A diferenciação de tais apresentações clínicas é de grande relevância para melhor abordagem terapêutica dos pacientes. Ampla variedade de intervenções terapêuticas está atualmente disponível para o tratamento do lúpus cutâneo. Nessa revisão, serão abordadas as principais opções terapêuticas, medicamentosas e não-medicamentosas, além das novas terapias ainda em estudo.


Cutaneous lupus is the most common systemic lupus erythematosus clinical manifestation. Skin lesions are classified according to the clinical and histopathologic features, which are of great relevancy for the management of the disease. Nowadays several therapeutic interventions are available to the treatment of cutaneous lupus. In this review we will approach the most widely used and also the new therapies which are under study.


Subject(s)
Humans , Male , Female , Adrenal Cortex Hormones , Antimalarials , Lupus Erythematosus, Cutaneous , Lupus Vulgaris , Lupus Erythematosus, Systemic/classification , Lupus Erythematosus, Systemic/therapy
9.
J. bras. med ; 73(5/6): 60-75, nov.-dez.1997. ilus
Article in Portuguese | LILACS | ID: lil-560024

ABSTRACT

O lúpus eritematoso cutâneo subagudo (LECS) é observado em cerca de 10 por cento dos pacientes com LE e foi caracterizado em 1979, por Sontheimer. A fotossensibilidade é marcante e o curso clínico relativamente benigno com febre, astenia e envolvimento do sistema nervoso central. O comprometimento renal é raro e quando ocorre é de forma discreta. O tratmento na maioria dos pacientes consiste de protetores solares, corticosteróides tópicos e antimaláricos.


Subacute cutaneous lupus erythematosus (SCLE) is in about 10% of patients with LE and it was characterized, in 1979, by Sontheimer. This subset exhibits prominent photosensitivity and relatively benign course. Fever, malaise and central nervous system involvement occur. Renal disease is mild and infrequent. SCLE condition in most patients is controlled with sunscreens, topical corticosteroid and antimalarial drugs.


Subject(s)
Humans , Male , Female , Lupus Erythematosus, Cutaneous/diagnosis , Lupus Erythematosus, Cutaneous/physiopathology , Lupus Erythematosus, Cutaneous/immunology , Lupus Erythematosus, Cutaneous/therapy , Autoimmunity , Fluorescent Antibody Technique
SELECTION OF CITATIONS
SEARCH DETAIL